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Mutations in the highly similar genes B-cell Translocation Gene 1 (BTG1) and BTG2 were 
identified in approximately 10-15% of non-Hodgkin lymphoma cases, which may suggest a 
direct involvement of BTG1 and BTG2 in malignant transformation. However, it is unclear 
whether or how disease-associated mutations impair the function of these genes. Therefore, we 
selected sixteen BTG1 variants based on in silico analysis. We then evaluated (i) the ability of 
these variants to interact with the known protein-binding partners CNOT7 and CNOT8, which 
encode the Caf1 catalytic subunit of the Ccr4-Not deadenylase complex; (ii) the activity of the 
variant proteins in cell cycle progression, (iii) translational repression and (iv) mRNA 
degradation. Based on these analyses, we conclude that mutations in BTG1 may contribute to 
malignant transformation and tumour cell proliferation by interfering with its anti-proliferative 









The BTG1 and BTG2 proteins are highly similar and mainly divergent in their C-terminus, 
which is extended in BTG1. Both proteins are part of the human B-cell translocation 
gene/transducer of ERBB2 (BTG/TOB) family of proteins, which also include BTG3, BTG4, 
TOB1 and TOB2 [1,2]. A common feature of the BTG/TOB proteins is their ability to inhibit 
cell cycle progression at the G1/S phase and reduce cell proliferation in a variety of cell types 
[3-7]. The BTG/TOB family members share sequence homology in the BTG domain that 
comprises the 104-106 N-terminal amino acids [8-10]. The best-characterised role of the BTG 
domain is in mediating protein-protein interactions [1,4,11-13,14 ,15]. All six BTG/TOB 
proteins can interact with the highly similar proteins CNOT7 and CNOT8 [4,11-13,16-19], 
which encode the Caf1 catalytic subunit of the Ccr4-Not deadenylase complex. This complex 
is involved in the shortening and removal of the mRNA poly(A) tail, which is the initial step 
in regulated mRNA degradation [20]. Several members of the BTG/TOB family also bind 
cytoplasmic poly(A)-binding protein PABPC1, which stimulates deadenylation by Caf1 
[17,21,22]. While TOB1 and TOB2 use a conserved PAM2 motif to interact with the C-
terminal domain of PABPC1 [22,23], BTG1 and BTG2 interact with the first RNA-recognition 
motif of PABPC1 [21]. In addition to the Caf1 paralogues and PABPC1, which are involved 
in post-transcriptional gene regulation, BTG1 and BTG2 have also been reported to interact 
with transcription factors, including HoxB9 [24] and nuclear receptors, including ER [12], 
and the methyltransferase PRMT1 [25]. 
Alterations in expression of the BTG1 and BTG2 paralogues are frequently observed in cancer 
[26-30]. In haematological malignancies, a high frequency of BTG1 deletions occur in cases of 
acute lymphoblastic leukaemia (ALL) [31]. Moreover, somatic variants of BTG1 and –to a 
lesser extend- BTG2 have been identified with relatively high frequency in non-Hodgkin’s 
lymphoma [32-37]. However, the effect of the amino acid substitutions on the activity of BTG1 
or BTG2 is not known. 
Here, we report the effect of lymphoma-associated mutations on the activity of BTG1. First, 
we used a combination of sequence analysis and molecular modelling to predict the functional 
consequences of previously identified mutations and selected a sub-set of BTG1 variants for 
functional analysis. Then, we analysed the ability of BTG1 variants to interact with the Caf1 
(CNOT7/CNOT8) catalytic subunit of the Ccr4-Not complex and functionally assessed the 




Materials and methods 
In silico analysis of BTG1 mutations 
Sequence information about BTG1 variants was collected from the COSMIC database (v65) 
[38] and additional reports [32-34,36]. The Sorting Intolerant From Tolerant (SIFT) webserver 
was used to predict the probability of amino acid substitutions as damaging (p < 0.05) [39]. 
To obtain a BTG1 structural model, the protein homology/analogy recognition engine 
(PHYRE) webserver was employed [40], which used the structure of the BTG2 protein as a 
template (72% identity; 94% similarity across 120 amino acids in structure 3E9V) [41]. The 
BTG1-CNOT7 structural model was prepared using UCSF Chimera [42] by superimposition 
of the BTG1 model with the structure of the BTG domain of TOB1 in complex with CNOT7 
(PDB 2D5R) (rmsd = 1.2 Å) [43]. 
 
Plasmid DNA preparation  





Yeast two hybrids analysis 
Plasmids pGal4-BD-HA-BTG1 and pGal4-AD-CNOT7 or pGal4-AD-CNOT8 were 
transformed into yeast strain YRG2 using the LiAc method as described by the manufacturer 
(Agilent), and grown in selective synthetic drop-out media without leucine or tryptophan 
(Sigma Aldrich). β-galactosidase activity of transformants was determined (Beta-Glo Reagent; 




HEK293 cells (n = 2  105) were seeded onto coverslips placed in 6-well plates and transfected 
with 1.0 µg pCMV5-HA-BTG1 plasmids or empty vector control using the calcium phosphate 
precipitation method. Forty-eight hours after transfection, cells were pulse labelled for 2 h 
using complete medium containing 20 µM of the thymidine analogue 5-ethynyl-2’-
deoxyuridine (EdU), fixed and stained following the manufacturer’s protocol (ThermoFisher 
Scientific; Click-iT EdU Alexa Fluor 594 Imaging Kit C10339). Cell nuclei were stained using 
Hoechst 33342 (5 μg/ml). For each slide, at least three images were acquired, each containing 
50-150 cells, using an EVOS FL Color Imaging System (Thermo Fisher Scientific). To count 
S-phase nuclei and the total number of nuclei in an unbiased manner, the ImageJ package 
(https://imagej.nih.gov/ij/) was used. The number of cells in S-phase determined using this 
method was comparable to the number of cells in S-phase reported using the EdU labelling 
method in combination with bivariate flow cytometry [44]. 
 
Western blotting 
Cells were harvested in PBS 48 hours post transfection and resuspended in lysis buffer (50 mM 
Tris-HCl pH 8.0, 150 mM NaCl, 5 mM MgCl2, 0.5 mM EDTA, 5% glycerol, 1% NP-40, 1 mM 
dithiotreitol). Soluble proteins were separated by 14% SDS-PAGE and expression of HA-
BTG1 variants was confirmed by western blotting using rat monoclonal antibody 3F10 (HA 
epitope tag, Roche, diluted 1:500). Goat polyclonal antibody C-20 (anti-γ tubulin, Santa Cruz 
sc-7396, diluted 1:1000) was used as a loading control. 
 
RNA tethering assay  
HEK293 cells (n = 80,000) were seeded into 12-well culture plates and transfected using the 
calcium phosphate method with 0.5 µg of plasmid pCIλN-BTG1 (or empty vector) and 0.5 µg 
of the reporter plasmid pRL-5BoxB. Cells were harvested 24 hours post-transfection before 
measuring luciferase activity using the BioLux Gaussia Luciferase Assay Kit (New England 
Biolabs, E3300S). Luciferase activity was normalised to total protein content determined using 
a Bradford assay (Sigma). 
Reverse transcriptase-quantitative PCR was used to measure the level of reporter mRNA. The 
levels of luciferase mRNA were determined using a TaqMan assay and GAPDH as a control. 




In silico evaluation of somatic mutations in BTG1  
Details of lymphoma-associated mutations in BTG1 were collected from literature reports and 
the Catalogue of Somatic Mutations In Cancer database (COSMIC) [38]. After discarding 
synonymous mutations, twenty-five BTG1 variants were identified in non-Hodgkin lymphoma 
(NHL) [32-36]. The majority of BTG1 variants are clustered in the BTG domain (19/25).  
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To evaluate the potential effect of amino acid substitutions on protein function, we used the 
Sorting Intolerant From Tolerant (SIFT) algorithm as a first step [39]. This algorithm is based 
on evolutionary conservation of protein sequences and predicts the potential impact of amino 
acid substitutions on protein function by calculating the probability for the altered amino acid 
to occur at that position. Overall, 60% of BTG1 variants (15/25) were predicted to be damaging 
using SIFT (p < 0.05) (Figure 1A; Table 1).  
 
Structural analysis of BTG1 variants  
To further understand the possible effect of the disease-associated amino acid substitutions, a 
structural model of the BTG1-Caf1/CNOT7 complex was prepared. First, a BTG1 homology 
model (residues 11-129) was prepared based on the structure of BTG2 [40]. Then, the BTG1 
model was superimposed on the BTG domain of TOB1 of the TOB1-Caf1/CNOT7 structure 
(Figure 1B) [43]. Mapping of the lymphoma-associated variants on the structural model 
indicated that most tolerated amino acid substitutions were located in the -helical N-terminal 
region away from the interaction surface with Caf1/CNOT7. By contrast, damaging variants 
were also present in the -stranded region that forms the interface with Caf1/CNOT7 (Figure 
1B). Similar results were obtained when BTG2 mutations were analysed (Supplementary 
Figure S1). 
 
Lymphoma-associated BTG1 amino acid substitutions affect the interaction with human 
Caf1  
To assess the possible effects of the amino acid substitutions on the function of BTG1, we 
selected 16 single amino acid variants based on the in silico analysis and investigated whether 
these variants were able to interact with the Caf1/CNOT7 and Caf1/CNOT8 subunits of the 
Ccr4-Not complex. To this end, we used the yeast two-hybrid assay based on the Gal4 DNA-
binding domain (BD) fused to BTG1 and the Gal4 activation domain (AD) fused to CNOT7 or 
CNOT8 (Figure 2). Robust β-galactosidase expression (>20-fold induction compared to 
background) was observed when Gal4-BD-HA-BTG1 was co-expressed with Gal4-AD-
CNOT7 or Gal4-AD-CNOT8 (Figure 2). 
Eight amino acid substitutions, R27H and F40C, which contain amino acid alterations in -
helices  and 2 (Figure 2A and 2D), L104H and I115V, located in -sheets 2 and 3 
(Figure 2B and 2E), M11I (loop L1), P58L (loop L1), G66V (helix 3) and N73K (loop L4) 
(Figure 2C and 2F), resulted in very low β-galactosidase activity and were therefore strongly 
impaired the interaction with CNOT7 and CNOT8.  
Expression of BTG1 variants Q36H () and L37M () did not result in reduced -
galactosidase activity when co-expressed with AD-CNOT7 (Figure 2A), although reduced 
reporter activity was observed when expressed with AD-CNOT8 (Figure 2D).Variants ∆N10 
BTG1, H2Y and E117D (loop L8) were able to stimulate β-galactosidase activity similarly to 
wild type BTG1, although BTG1 E117D was marginally disrupted in the interaction with 
CNOT8. Interestingly, E59D (loop L2), which was selected due to the fact that the conservative 
amino acid change was located close to the surface of the interaction interface, showed a partial 
disruption in the interaction with CNOT7 and CNOT8 (Figure 2C and 2F). Taken together, 
these results indicate that the majority of the BTG1 variants displayed a reduced ability to 
interact with the CNOT7 and CNOT8 subunits of the Ccr4-Not complex. Similar results were 
obtained when BTG2 mutations were analysed (Supplementary Figure S2). 
 
The effect of lymphoma-derived BTG1 mutations on the regulation of cell proliferation  
Next, we investigated whether the ability of BTG1 to inhibit cell cycle progression was affected 
by lymphoma-associated amino acid substitutions. To this end, HEK293T cells were 
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transfected with HA-BTG1 expression vectors and the number of cells in S-phase was 
determined via incorporation of the thymidine analogue EdU (Figure 3).  
Compared to control-transfected cells, cells expressing wild type BTG1 consistently showed a 
reduction of cells in S-phase as expected based on its anti-proliferative activity (Figure 3A). 
By contrast, expression of variants R27H, F25C, F40C (Figure 3A), L104H, I115V 
(Figure 3B), M11I, P58L, G66V (Figure 3C), N73K and E117D (Figure 3D), L37M and 
L94V (Figure 3F) did not inhibit cell cycle progression. In each case, western blot analysis 
confirmed expression levels similar to wild type BTG1, except for variant F40C, which 
consistently showed reduced expression, indicating that this variant may be unstable.  
Expression of variants H2Y and Q36H resulted in reduced cell cycle progression to a level 
similar to that of wild type BTG1 (Figure 3E). This was also observed with the BTG1 variant 
lacking the first methionine start codon, which is predicted to result in the deletion of the first 
ten amino acids (BTG1 N10) (Figure 3F). Variant E59D, which was predicted to be tolerated 
by the SIFT algorithm, has reduced affinity for CNOT7 and CNOT8, and is also unable to 
inhibit cell cycle progression (Figure 3F). 
Taken together, these results indicate that lymphoma-associated amino acid substitutions 
frequently interfere with the ability of BTG1 to inhibit cell cycle progression.  
 
Regulation of mRNA translation and degradation of a tethered reporter mRNA by BTG1 
variants    
Because of the high similarity between BTG1 and BTG2, it is expected that the anti-
proliferative function of these proteins is mediated through their role in mRNA decay and 
translational repression [16,21]. Therefore, we tested the activity of the selected BTG1 variants 
in mRNA degradation and translational repression. Thus, we expressed BTG1 fused to the N 
peptide together with a luciferase reporter mRNA containing five Box B sequence motifs 
located in the 3’ untranslated region. As expected, expression of N-HA-BTG1 repressed 
translation of a tethered reporter mRNA as measured by luciferase activity (Figure 4A-F). The 
decrease in luciferase activity was due to degradation of the tethered reporter, as the mRNA 
levels of the reporter were also reduced by a similar amount (Figure 4A-F). 
Next, the sixteen BTG1 variants were expressed as N-fusion proteins, and their ability to 
repress translation and induce degradation of a tethered luciferase reporter evaluated. Variants 
F40C (Figure 4A) and G66V (Figure 4C) showed impaired ability to repress luciferase 
activity and degrade the reporter mRNA. In case of F40C, residual activity remained, whereas 
G66V was unable to inhibit translation and induce degradation of the reporter mRNA.  
The activities of variants H2Y, Q36H (Figure 4E) and N10 (Figure 4F) were comparable to 
that of wild type N-HA-BTG1 and both luciferase activity and reporter mRNA levels were 
reduced compared to empty vector-transfected cells. Upon expression of N-HA-BTG1 
L104H, a modest reduction in luciferase activity was observed compared to wild type BTG1, 
while the reduction of reporter mRNA levels compared to empty vector control was moderate 
(Figure 4B).  
Surprisingly, expression of N-HA-BTG1 containing amino acid substitutions F25C, R27H 
(Figure 4A), I115V (Figure 4B), M11I, P58L (Figure 4C), N73K, E117D, E59D (Figure 
4D), L37M, and L94V (Figure 4F) resulted in full repression of luciferase activity and 
degradation of the reporter mRNA even though these variants were impaired in their 
interactions with CNOT7 and/or CNOT8 (Figure 2), and unable to inhibit cell proliferation 
(Figure 3). For all variants, western blot analysis indicated that they were all expressed to 
similar levels as N-HA-BTG1. Comparable results were obtained when BTG2 mutations were 




Pleiotropic effects of amino acid substitutions on BTG1 activity 
Because the analysed mutations displayed pleiotropic effects on BTG1 activities, we used 
hierarchical clustering to sort the selected BTG1 variants and identified four groups (Figure 5). 
First, three mutations (resulting in amino acid substitutions H2Y, Q36K and a deletion of the 
ten N-terminal amino acids) did not interfere with BTG1 activities under the conditions used 
(group I). BTG1 variants in the second group (L37M, L94V, E117D, F25C and E59D), retained 
a moderate ability to bind the Caf1 paralogues CNOT7 and CNOT8, and displayed substantial 
defects in the ability of BTG1 to reduce cell cycle progression (group II). In group III (I115V, 
R27H, M11I, and N73K), variants also displayed defects in the ability of BTG1 to reduce cell 
cycle progression, and displayed substantial defects in the interaction with CNOT7 and 
CNOT8. Finally, three mutations (resulting in amino acid substitutions G66V, L104H and 
F40C) severely interfered with BTG1 activity and behaved under the tested conditions as the 
controls lacking BTG1 expression (group IV). In addition to defects in Caf1 (CNOT7/CNOT8) 
binding and impaired ability to inhibit cell cycle progression, variants in this group were also 
unable to induce mRNA degradation and inhibit mRNA translation when tethered to a reporter 




In recent years, several reports revealed frequent mutations in BTG1 and –less commonly– 
the highly similar gene BTG2 in non-Hodgkin lymphoma [32-36]. Here, we show that 
lymphoma-associated point mutations in BTG1 frequently affect the function of the gene 
product.  
The observation that BTG1 variants with impaired binding to the Caf1 paralogues CNOT7 
and CNOT8 are also defective in the ability to inhibit cell cycle progression correlates well 
with previous observations of BTG2, which used designed mutations that disrupt the 
interaction with Caf1 [16,21]. Contrary to these studies, however, some BTG1 variants are 
still able to induce degradation of a tethered reporter even though they are unable to interact 
with Caf1. In this respect, it should be noted that combined knockdown of CNOT7 and 
CNOT8 did not fully rescue mRNA levels and luciferase activity of the reporter when 
tethered by BTG2 [16]. It has been reported that BTG1 and BTG2 also interact with other 
proteins, including HoxB9, PRMT1 and nuclear receptors, such as ER, that are involved in 
cancer [12,24,25]. Inactivating mutations in BTG1 and BTG2 may also impact on protein-
protein interactions with these partners and contribute to the tumour phenotype. 
Due to their similarity, it is likely that a significant proportion of mutations in BTG2 would 
interfere with the activity of the gene product in a similar manner as BTG1 mutations. 
Reduced expression of BTG1 or BTG2 is observed in several tumour types [26-30], and 
downregulation of BTG1 in lymphoma is a common feature in c-MYC induced lymphoma 
[45]. The mIR-17-92 cluster, which is frequently amplified in B-cell lymphomas [46], is 
upregulated by increased c-MYC activity. In turn, this cluster suppresses the expression of 
several genes, including BTG1, that contribute to the tumour phenotype. In agreement with 
an important role of BTG1 in lymphoma, knockdown of BTG1 can overcome the 
proliferative arrest following inactivation of c-MYC [45]. It may therefore be that 
inactivation of BTG1 or BTG2 by single base pair mutations contributes to tumour 
development of non-Hodgkin lymphoma. It may be that both proteins can substitute each 
other’s function and it could be speculated that inactivation of BTG1 or BTG2 by single base 
mutations reduces their combined activity that is functionally similar to reduced expression of 
BTG1 or BTG2 observed in other tumour types. In agreement with this notion, there is a 
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statistically significant overlap between inactivation of BTG1 and BTG2 in diffuse large B 
cell lymphoma [37].  
Altered expression of other members of the BTG/Tob family of proteins are also implicated 
in cancer [47]. Altered expression of BTG3 and changes in the phosphorylation status of 
TOB1 are frequently observed in lung cancer [48,49]. On the other hand, high expression of 
TOB1 is associated with poor prognosis in breast cancer [50,51]. Thus, further understanding 
of the molecular mechanism(s) by which these proteins exert their effects will lead to an 
improved model for the role of these proteins in cancer development and progression. 
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1 1 M → I G>A ATG>ATA 0 Damaging DLBCL 33 
2 2 H → Y C>T CAT> TAT 0.037 Damaging ABC,GCB 32 
3 3 P → R C>G CCC> CGC 0.069 Tolerated DLBCL 33 
4 5 Y → H T>C TAC>CAC 0.409 Tolerated DLBCL 33 
5 11 M → I G>A ATG>ATA 0.028 Damaging DLBCL 33 
6 23 S → A T>G TCC> GCC 0.427 Tolerated DLBCL 33 
7 25 F → C T>G TTT>TGT 0.001 Damaging DLBCL 33 
8 27 R → H G>A CGC> CAC 0.039 Damaging GCB 32 
9 31 L → F C>T CTC>TTC 0.726 Tolerated DLBCL 33 
10 36 Q → H G>C CAG> CAC 0.006 Damaging ABC 32 
11 37 L → M C>A CTG>ATG 0.02 Damaging GCB 32,35 





13 38 Q → E C>G CAG> GAG 0.444 Tolerated GCB 32 
14 40 F → C T>G TTC>TGC 0 Damaging DLBCL 33 
15 46 E → D G>C GAG> GAC 0.239 Tolerated GCB 32 
16 46 E → Q G>C GAG>CAG 0.155 Tolerated DLBCL 33 
17 58 P → L C>T CCA> CTA 0 Damaging ABC 32 
18 59 E → D A>T GAA>GAT 0.541 Tolerated DLBCL 33 
19 66 G → V G>T GGT>GTT 0.001 Damaging Unknown 36 





21 73 N → K C>A AAC>AAA 0.001 Damaging Unknown 36 
22 94 L → V C>G CTG> GTG 0.002 Damaging GCB 32 
23 104 L → H T>A CTC>CAC 0 Damaging DLBCL 36 
24 115 I → V A>G ATT>GTT 0.003 Damaging DLBCL 33 
25 117 E → D G>T GAG>GAT 0.022 Damaging DLBCL 33 
26 149 C → * T>A TGT> TGA - - DLBCL 36 
27 165 N → S A>G AAT>AGT 0.46 Tolerated DLBCL 33 
aFollicular Follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), germinal centre B-cell (GCB), 
activated B-cell (ABC) and multiple myeloma (MM). SIFT prediction software v 1.03 was used [39]. The zygosity 









Figure 1. In silico analysis of lymphoma-associated BTG1 variants.  
(A) Overview of lymphoma-associated mutations in BTG1. Mutations predicted to be 
damaging by the SIFT algorithm [39] are shown in red (p < 0.05); mutations in blue are 
predicted to be tolerated. The conserved BTG domain is shown in light grey; conserved regions 
Box A, B and C are shown in dark grey. (B) Structural mapping of BTG1 variants. The BTG1 
model was generated by homology modelling [40]. The BTG1 model (light khaki) was then 
superimposed on the BTG domain of TOB1 in complex with CNOT7 (white) [43].  
 
Figure 2. Impaired interactions between lymphoma-associated BTG1 variants and the 
CNOT7 and CNOT8 deadenylase subunits of the Ccr4-Not complex.  
(A-C) Yeast two-hybrid interactions between CNOT7 and BTG1 variants located in (A) α-
helical regions, (B) β-sheets, or (C) loops. (D-F) Yeast two-hybrid interactions between 
CNOT8 and BTG1 variants located in (D) α-helical regions, (E) β-sheets, or (F) loops. Error 
bars indicate the standard error of the mean (n = 3). P values were calculated using a one-way 
Anova and Dunnett’s post-hoc test. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.  
 
Figure 3. Lack of anti-proliferative activity in lymphoma-associated BTG1 variants.  
(A-F) Effect of expression of lymphoma-associated BTG1 variants on cell cycle progression. 
Top panels, lysates of transfected cells were separated by SDS-PAGE and immunoblots 
probed with anti-HA antibodies. Antibodies recognising -tubulin were used as loading 
controls. Bottom panels, the percentage of cells in S-phase was determined by incorporation 
of the thymidine analogue EdU in HEK293T cells expressing BTG1 variants. Error bars 
indicate the standard error of the mean (n = 3). P values were calculated using a one-way 
Anova and Tukey’s post-hoc test. * p <0.05, ** p<0.01, *** p <0.001 and **** p<0.0001 
compared to control cells transfected with pCMV5-HA-BTG1.  
 
Figure 4. Lymphoma-associated amino acid substitutions of BTG1 do not generally 
interfere with degradation of a tethered reporter mRNA.  
(A-F) Top panels, lysates of transfected cells were separated by SDS-PAGE and 
immunoblots probed with anti-HA antibodies to detect the N-HA-BTG1 variants. 
Antibodies recognising -tubulin were used as loading controls. Bottom panels, luciferase 
activity and reporter mRNA levels obtained after expression of wild type BTG1 and 
lymphoma-associated BTG1 variants. HEK293T cells were co-transfected with a reporter 
plasmid containing a Renilla luciferase expression cassette containing five box B sequences 
in the 3′ UTR and a plasmid expressing λN-HA-BTG1 fusion proteins. Levels of the 
luciferase reporter mRNA were determined by reverse transcriptase-quantitative PCR. Error 
bars indicate the standard error of the mean (n = 3). P values were calculated by a one-way 
ANOVA with Tukey’s post-hoc test. * P < 0.05, *** p <0.001 and **** p <0.0001 
(compared to the cells expressing wild type λN-HA-BTG1).  
 
Figure 5. Pleiotropic effects of amino acid substitutions on BTG1 activity. 
Heat map representing amino acid substitutions clustered based on (semi) quantitative two-
hybrid interaction data (binding to CNOT7 and CNOT8); inhibition of cell cycle progression 
upon expression of BTG1 (percentage of cells in S-phase), and the influence on luciferase 
expression (Luc mRNA compared to empty vector control) and activity (Luc activity 
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